EKF Diagnostics, the point of care diagnostics company, announced the launch of the Quo-Lab HbA1c analyser. It has been billed as a revolution in HbA1c measurement because it combines high accuracy with low cost and easy-to-use technology.
It has been developed to provide a point of care device that meets the needs of clinics and laboratories in developing countries where diabetes is an increasingly large public health issue and resources are limited. It delivers lab-accurate results within four minutes. The new analyser will be ready for shipping in Q1 2012.
The EKF share price has increased by 10% over the past year.
EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.
